NCT05823337

Brief Summary

Gestational diabetes mellitus (GDM) occurs in approximately 15% of all pregnancies worldwide.GDM can lead to the development of type 2 diabetes mellitus (T2DM) later in a woman's life. Babies of mothers with GDM have a greater risk of developing T2DM and cardiovascular disease than infants of women without GDM. The degree of insulin resistance is directly proportional to the accumulated free radicals. Selenium functions as an active site component of an antioxidant enzyme, glutathione peroxidase, and helps scavenge free radicals. In addition, an experimental study has shown that selenium provides activation by binding to insulin receptors and lowers blood sugar by increasing glucose uptake by cells. According to all this information, we aimed to evaluate the effect of selenium on blood sugar regulation in pregnant patients.

Trial Health

43
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
220

participants targeted

Target at P75+ for not_applicable

Timeline
Completed

Started Jul 2023

Shorter than P25 for not_applicable

Geographic Reach
1 country

1 active site

Status
unknown

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

April 10, 2023

Completed
11 days until next milestone

First Posted

Study publicly available on registry

April 21, 2023

Completed
2 months until next milestone

Study Start

First participant enrolled

July 1, 2023

Completed
2 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

August 30, 2023

Completed
1 day until next milestone

Study Completion

Last participant's last visit for all outcomes

August 31, 2023

Completed
Last Updated

June 28, 2023

Status Verified

June 1, 2023

Enrollment Period

2 months

First QC Date

April 10, 2023

Last Update Submit

June 27, 2023

Conditions

Keywords

seleniumgestational diabetes mellitusglycemic control

Outcome Measures

Primary Outcomes (3)

  • five day fasting glucose average

    five-day fasting glucose average during treatment after one month of treatment

    four weeks

  • five-day first hour postprandial glucose average

    five-day first hour postprandial glucose average during treatment after one month of treatment

    four weeks

  • five-day second hour postprandial glucose average

    five-day second hour postprandial glucose average during treatment after one month of treatment

    four weeks

Study Arms (2)

only given diet therapy

ACTIVE COMPARATOR

only diet theraphy

Dietary Supplement: only diet

given diet therapy and selenium

EXPERIMENTAL

diet theraphy and 200 mcg selenium

Dietary Supplement: selenium+ diet

Interventions

selenium+ dietDIETARY_SUPPLEMENT

Selenium functions as an active site component of an antioxidant enzyme, glutathione peroxidase, and helps scavenge free radicals.

Also known as: diet
given diet therapy and selenium
only dietDIETARY_SUPPLEMENT

diet suitable for pregnancy

only given diet therapy

Eligibility Criteria

Age18 Years - 45 Years
Sexfemale
Healthy VolunteersNo
Age GroupsAdult (18-64)

You may qualify if:

  • Presence of one or more of the values of fasting blood glucose ≥ 92, 1st hour ≥ 180 and 2nd hour ≥ 153 among pregnant patients for whom we had an oral glucose tolerance test between 24 and 28 weeks of gestation
  • single pregnancy
  • to 45 years old

You may not qualify if:

  • chronic disease (thyroid dysfunction, acute/chronic liver disease, acute/chronic kidney disease, hypertension )
  • Patients with a diagnosis of insulin resistance or diabetes
  • Those who use drugs other than iron, vitamin D and multivitamin support
  • multiple pregnancy
  • patients under 18 years old
  • Patients over 45 years old

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Medipol University

Istanbul, Turkey (Türkiye)

Location

MeSH Terms

Conditions

Diabetes, Gestational

Interventions

Diet

Condition Hierarchy (Ancestors)

Pregnancy ComplicationsFemale Urogenital Diseases and Pregnancy ComplicationsUrogenital DiseasesDiabetes MellitusGlucose Metabolism DisordersMetabolic DiseasesNutritional and Metabolic DiseasesEndocrine System Diseases

Intervention Hierarchy (Ancestors)

Nutritional Physiological PhenomenaDiet, Food, and NutritionPhysiological Phenomena

Central Study Contacts

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
SINGLE
Who Masked
OUTCOMES ASSESSOR
Purpose
TREATMENT
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Ass.prof. Ece YİĞİT

Study Record Dates

First Submitted

April 10, 2023

First Posted

April 21, 2023

Study Start

July 1, 2023

Primary Completion

August 30, 2023

Study Completion

August 31, 2023

Last Updated

June 28, 2023

Record last verified: 2023-06

Locations